Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore advanced strategies and solutions for developing bi-specific antibodies as cancer therapeutics in this 33-minute webinar presented by Roumen Bogoev, MSc, head of segment marketing for GenScript. Learn how bi-specific antibodies overcome limitations of traditional monoclonal antibodies by targeting two distinct antigens simultaneously, enhancing therapeutic efficacy through mechanisms such as redirecting immune effector cells to tumor sites, blocking multiple oncogenic pathways, and bridging tumor cells with cytotoxic T-lymphocytes. Discover key therapeutic mechanisms including T-cell engagement through CD3 binding, dual checkpoint inhibition, and simultaneous targeting of resistance pathways. Understand the development and manufacturing challenges associated with bi-specific antibodies and examine GenScript's integrated development platform that addresses these obstacles through expedited processes, novel expression systems, and innovative purification strategies. Gain insights into scalable production methods for creating stable, potent bi-specific constructs with improved safety profiles and enhanced anti-tumor activity, making this webinar valuable for researchers, biotechnology professionals, and pharmaceutical scientists working in cancer therapeutics development.
